Biomarkers of nivolumab benefit in resectable non-small cell lung cancer - Nature

Potential predictive biomarkers of perioperative nivolumab therapy benefit in non-small cell lung cancer are identified from evaluable participants in the CheckMate 77T trial.

Raccontata danature.com